1. Validating controlled attenuation parameter in the assessment of hepatic steatosis in living liver donors
- Author
-
Khalid Bzeizi, Roberto Troisi, Mohamed Shawkat, Dieter C. Broering, Saleh Alabbad, Saleh Alqahthani, Ali Albenmousa, Faisal Abaalkhail, Saad Alghamdi, Waleed Al-Hamoudi, Ahmad Jaafari, Broering, D., Shawkat, M., Albenmousa, A., Abaalkhail, F., Alabbad, S., Al-Hamoudi, W., Alghamdi, S., Alqahthani, S., Jaafari, A., Troisi, R., and Bzeizi, K.
- Subjects
Male ,Steatosis ,medicine.medical_treatment ,Biopsy ,Aminotransferases ,Liver transplantation ,Pathology and Laboratory Medicine ,Gastroenterology ,Biochemistry ,Cytopathology ,Positive predicative value ,Living Donors ,Medicine and Health Sciences ,Medicine ,Multidisciplinary ,medicine.diagnostic_test ,Liver Diseases ,Fatty liver ,Living-Related Liver Transplantation ,Enzymes ,Liver ,Liver biopsy ,Elasticity Imaging Techniques ,Liver Fibrosis ,Female ,Research Article ,Adult ,medicine.medical_specialty ,Science ,Lipoproteins ,Surgical and Invasive Medical Procedures ,Gastroenterology and Hepatology ,Young Adult ,Digestive System Procedures ,Transferases ,Internal medicine ,Humans ,Transplantation ,business.industry ,Biology and Life Sciences ,Proteins ,Organ Transplantation ,medicine.disease ,Liver Transplantation ,Fatty Liver ,Anatomical Pathology ,Enzymology ,Transient elastography ,business ,Body mass index - Abstract
Introduction Hepatic steatosis (HS) negatively impacts transplant outcomes in living liver donors. To date, liver biopsy is preferred for HS evaluation. This study aims to evaluate the measurement of controlled attenuation parameter (CAP) as a diagnostic tool of HS in living liver donors. Methods Candidates recruited to this study, conducted from April 2016 to February 2020, were potential donors who had undergone transient elastography using Fibroscan® and CAP measurements at liver segments VI and VII, followed by liver biopsy. The HS grades from liver biopsy were classified as S0 (66%). For CAP, they were S0 (≤218dB/m), S1 (218-249dB/m)), S2 (250-305dB/m)), and S3 (>305dB/m)). The CAP measurements were compared with the liver biopsy results. Results Of the 150 potential donors [male, 73.3%; mean age, 30.0±7.0 years; body mass index (BMI), 24.7±3.5kg/m2], 92 (61.3%) had no or mild HS, while 58 (38.7%) and 10% had moderate to severe HS based on CAP and liver biopsy, respectively. Subjects with moderate to severe HS per CAP were mostly males (0.014), and had higher BMI (p = .006), alanine aminotransferase (ALT) (.001), gamma-glutamyl transferase (.026), and high-density lipoprotein (.008). On multivariate analysis, high ALT (OR, 1.051; 95% CI, 1.016–1.087; p = .004) was a predictor of significant HS. The sensitivity, specificity, positive and negative predictive values of CAP to detect significant HS were 93.3%, 67.4, 24.1%, and 98.9%, respectively. Conclusion The high sensitivity and negative predictive values of CAP make it a good screening test to exclude significant HS in potential living liver donors which, in turn, can help avoid unnecessary liver biopsies.
- Published
- 2020